drugset / Trial / NCT07281924
Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis
NaSingle-groupOpen-labelTreatment
Summary
This study is being done to see if combining HEPZATO KIT™ with nivolumab and relatlimab (Opdualag™) in the first line setting in patients with metastatic melanoma with liver metastasis is safe, tolerable, and will have a synergistic effect leading to improved clinical outcomes compared to the historic cohort of patients with liver metastasis treated with combination immune checkpoint inhibitor therapy.
Timeline
- Start
- 2026-07
- Primary completion
- 2030-12
- Completion
- 2030-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Melphalan | Small molecule | 3 mg/kg | — |
| Subject | Nivolumab | Monoclonal antibody | 480 mg | — |
| Subject | Relatlimab | Monoclonal antibody | 160 mg | — |